Overview

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.

Phase:

Phase 1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

Chugai Pharma USA